![Stefan Ryser](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stefan Ryser
Vorstandsvorsitzender bei
Trellis Bioscience, Inc.
Profil
Stefan Ryser was the founder of International Biomedicine Management Partners AG, founded in 1998, holding the title of Chief Executive Officer in 2000.
Dr. Ryser is the founder of Bear Stearns Health Innoventures Management LLC, with the title of Founding Partner from 2000 to 2009.
Current job includes President, Chief Executive Officer & Director at Trellis Bioscience, Inc. since 2013.
Former jobs include Chief Executive Officer & Director at A-CUBE, Inc., Director at Arena Pharmaceuticals, Inc., Director at Achillion Pharmaceuticals, Inc., Managing Director at Bear Stearns Asset Management, Inc., Director at Entelos, Inc., Director at Tolerx, Inc., Director at Genaissance Pharmaceuticals, Inc., Director at Cytokinetics, Inc., Director & Senior VP-Corporate Strategy at Telik, Inc. from 1998 to 2009, and Head-Research Staff at Hoffmann-La Roche, Inc. from 1989 to 1997.
Education includes undergraduate and doctorate degrees from the University of Basel.
Aktive Positionen von Stefan Ryser
| Unternehmen | Position | Beginn |
|---|---|---|
Trellis Bioscience, Inc.
 Trellis Bioscience, Inc. BiotechnologyHealth Technology Develops treatments for infectious diseases, cancer and oncology indications | Vorstandsvorsitzender | 01.01.2013 |
Ehemalige bekannte Positionen von Stefan Ryser
| Unternehmen | Position | Ende |
|---|---|---|
Telik, Inc.
 Telik, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and commercializing novel small molecule drugs to treat serious diseases | Direktor/Vorstandsmitglied | 01.08.2009 |
Bear Stearns Health Innoventures Management LLC
 Bear Stearns Health Innoventures Management LLC Investment ManagersFinance BSHI seeks to invest in private companies with innovative research & development in areas of biotechnology. The firm prefers to be the lead investor in companies with the following characteristics: consistency with vision based on potential to enhance productivity, quality and cost-effectiveness of health care, market segment at an inflection point, innovative product or service and a proprietary, defensible and sustainable technology platform. They also look for management excellence, manageable regulatory risks and a viable business model based on market size, demand/medical need, sustainable margins, suitability for alliances and technology-into-product feasibility. | Chief Investment Officer | 31.03.2009 |
| ACHILLION PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 27.04.2007 |
International Biomedicine Management Partners AG
 International Biomedicine Management Partners AG Investment ManagersFinance Acts as an alternative investment manager | Gründer | 01.04.2000 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Corporate Officer/Principal | 31.12.1997 |
Ausbildung von Stefan Ryser
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
61
Beziehungen ersten Grades
16
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 16 |
|---|---|
Roche Holding AG
 Roche Holding AG Pharmaceuticals: MajorHealth Technology Operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics | Health Technology |
Bear Stearns Asset Management, Inc.
 Bear Stearns Asset Management, Inc. Investment ManagersFinance Bear Stearns Asset Management, Inc. is an asset management firm and broker/dealer located in New York City. The firm is a subsidiary of JPMorgan Asset Management, Inc. and their ultimate parent is JPMorgan Chase & Co., Inc. (NYSE: JPM). They manage equity and fixed-income separate accounts, mutual funds, hedge funds, private equity funds and venture capital funds. Their clients include corporations, municipal governments, multi-employer plans, endowments, foundations, family groups and high net-worth individuals | Finance |
Telik, Inc.
Telik, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovering, developing and commercializing novel small molecule drugs to treat serious diseases | Health Technology |
Genaissance Pharmaceuticals, Inc.
 Genaissance Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops and uses genetic information to diagnostic and therapeutic products | Health Technology |
Arena Pharmaceuticals, Inc.
 Arena Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical products | Health Technology |
Tolerx, Inc.
 Tolerx, Inc. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
Cytokinetics, Inc.
 Cytokinetics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes novel drug products | Health Technology |
Trellis Bioscience, Inc.
Trellis Bioscience, Inc. BiotechnologyHealth Technology Develops treatments for infectious diseases, cancer and oncology indications | Health Technology |
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes treatments for infectious diseases | Health Technology |
Entelos, Inc.
 Entelos, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical trial partner that supports drug research and development teams | Commercial Services |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Operates as a biotech company that develops pharmaceutical and diagnostic solutions | Health Technology |
Bear Stearns Health Innoventures Management LLC
Bear Stearns Health Innoventures Management LLC Investment ManagersFinance BSHI seeks to invest in private companies with innovative research & development in areas of biotechnology. The firm prefers to be the lead investor in companies with the following characteristics: consistency with vision based on potential to enhance productivity, quality and cost-effectiveness of health care, market segment at an inflection point, innovative product or service and a proprietary, defensible and sustainable technology platform. They also look for management excellence, manageable regulatory risks and a viable business model based on market size, demand/medical need, sustainable margins, suitability for alliances and technology-into-product feasibility. | Finance |
University of Basel
 University of Basel Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
International Biomedicine Management Partners AG
International Biomedicine Management Partners AG Investment ManagersFinance Acts as an alternative investment manager | Finance |
The European Association for Bioindustries | |
A-CUBE, Inc.
 A-CUBE, Inc. BiotechnologyHealth Technology Develops novel antibodies | Health Technology |
